The ENSEMBLE clinical trial, which aimed to test the safety and efficacy of the Johnson & Johnson vaccine (Ad26.COV2.S) against moderate to severe coronavirus disease 2019 (COVID-19), was conducted in ...
In a recent study posted to the Research Square* preprint server under consideration at a Nature Portfolio journal, researchers demonstrated that a modified vaccinia virus Ankara (MVA) vector ...
Factors associated with readmission to the same hospital within 30 days of discharge in patients who received surgical treatment for head and neck cancer: An NCDB analysis. This is an ASCO Meeting ...
Vaccine effectiveness against coronavirus disease 2019 (Covid-19) wanes over time, and boosters are now recommended for residents of the United States starting at the age of 12 years. 1 Clinical ...
Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO ...
Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results